膀胱微乳头状尿路上皮癌:疾病特征与治疗结局的系统评价与荟萃分析
该系统评价与荟萃分析共纳入758篇报告、3154例患者,其中28篇用于定性分析、15篇用于定量分析。结果显示,T1期微乳头状膀胱癌早期根治性膀胱切除的5年癌症特异性生存率为81%–100%,经尿道膀胱肿瘤电切联合卡介苗为60%–85%;新辅助化疗虽可使部分患者达到病理完全缓解,但未改善生存;根治性膀胱切除后微乳头成分与生存无显著关联。
要点
- T1期微乳头状膀胱癌早期根治性膀胱切除的5年癌症特异性生存率高于经尿道电切联合卡介苗。
- 新辅助化疗未显著改善无复发生存、癌症特异性生存或总生存。
- 根治性膀胱切除后,微乳头成分与生存结局无显著关联。
核心结论
- 微乳头状膀胱尿路上皮癌与晚期疾病 clinicopathological 特征相关,但根治性膀胱切除后并不与更差的生存结局相关。
- 新辅助化疗可使显著比例患者达到病理降期,但未转化为更好的生存获益。
- cT1期患者的最佳治疗仍存在争议。
研究设计与样本
- 系统评价与荟萃分析,遵循PRISMA声明和Cochrane干预系统评价手册进行系统检索。
- 共识别758篇报告、合计3154例患者,其中28篇纳入定性分析、15篇纳入定量分析。
- 主要终点为无复发生存、癌症特异性生存和总生存。
主要发现
- T1期微乳头状膀胱癌早期根治性膀胱切除的5年癌症特异性生存率为81%–100%,经尿道膀胱肿瘤电切联合卡介苗为60%–85%。
- 报告新辅助化疗的研究中,病理完全缓解(ypT0)率为11%–55%。
- 新辅助化疗未改善无复发生存(HR 1.23,95%CI 0.52–2.93,p=0.6)、癌症特异性生存(HR 0.9,95%CI 0.48–1.7,p=0.8)或总生存(HR 1.35,95%CI 0.98–1.86,p=0.1)。
- 校正病理特征后,根治性膀胱切除标本中微乳头成分与无复发生存(HR 1.25,95%CI 0.88–1.78,p=0.2)、癌症特异性生存(HR 0.96,95%CI 0.57–1.6,p=0.9)或总生存(HR 1.20,95%CI 0.88–1.62,p=0.3)无显著关联。
关键数值与推荐
- T1期微乳头状膀胱癌:早期根治性膀胱切除5年癌症特异性生存率81%–100%,经尿道膀胱肿瘤电切联合卡介苗60%–85%。
- 新辅助化疗后病理完全缓解(ypT0)率11%–55%。
临床怎么用
- 微乳头状膀胱癌不必然需要采用不同的治疗算法,但每例应结合其他临床病理因素个体化讨论。
- cT1期患者的最佳治疗选择仍需个体化决策。
- 新辅助化疗虽可带来病理降期,但不应期望其显著改善生存结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: The optimal treatment of urothelial bladder cancer (UBC) with micropapillary (MP) variant histology is not clear. OBJECTIVE: To review the current literature on disease characteristics and treatment outcomes of MP UBC. EVIDENCE ACQUISITION: A systematic search was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement and the Cochrane Handbook for Systematic Reviews of Interventions. The primary end points were recurrence-free survival (RFS), cancer-specific survival (CSS), and overall survival (OS). EVIDENCE SYNTHESIS: We identified 758 reports comprising a total of 3154 patients, of which 28 and 15 articles were selected for qualitative and quantitative analysis, respectively. In patients with T1 MP UBC, the 5-yr CSS rates for early radical cystectomy (RC) ranged from 81% to 100%, while they were between 60% and 85% for transurethral resection of the bladder and Bacillus Calmette-Guérin (BCG). In studies reporting on neoadjuvant chemotherapy (NAC), the rates of complete pathological response (ypT0) ranged from 11% to 55%. Nevertheless, the use of NAC did not improve RFS (hazard ratio [HR] 1.23, 95% confidence interval [CI] 0.52-2.93, p=0.6), CSS (HR 0.9, 95% CI 0.48-1.7, p=0.8), or OS (HR 1.35, 95% CI 0.98-1.86, p=0.1). Fifty-three percent (95% CI 43-63%) of patients who underwent RC alone had locally advanced disease (≥pT3), and 43% (95% CI 33-52%) were harbouring lymph node metastases. MP component at RC was not significantly associated with worse RFS (HR 1.25, 95% CI 0.88-1.78, p=0.2), CSS (HR 0.96, 95% CI 0.57-1.6, p=0.9), or OS (HR 1.20, 95% CI 0.88-1.62, p=0.3) when adjusted for pathological features. CONCLUSIONS: While MP UBC is associated with clinicopathological features of advanced disease, it is not associated with worse survival outcomes in patients undergoing RC. NAC results in pathological downstaging in a significant number of patients. Nevertheless, this does not translate into better survival outcomes. The optimal treatment of patients with cT1 remains controversial. PATIENT SUMMARY: Our results suggest that micropapillary urothelial bladder cancer does not necessarily mandate different treatment algorithms. Nevertheless, each case should be discussed individually considering other clinicopathological factors.
引用
- Abufaraj M, Foerster B, Schernhammer E, et al. Micropapillary Urothelial Carcinoma of the Bladder: A Systematic Review and Meta-analysis of Disease Characteristics and Treatment Outcomes. Eur Urol. 2018. PMID: 30553613. doi:10.1016/j.eururo.2018.11.052
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。